News Breaks |
|
|
| February 4, 2013 |
| 17:10 EDT |  | GILD | Gilead sees FY13 revenue $10B – $10.2B, consensus $10.44B
The company also sees Non-GAAP product gross margin 74%-76% and a diluted EPS impact of acquisition related, restructuring and stock-based compensation expenses to be 21c-24c. |
|
|
News For GILD From The Last 14 Days Check below for free stories on GILD the last two weeks. |
|
|
| May 23, 2013 |
| 10:27 EDT |  | GILD | Gilead has a conference call hosted by JPMorgan
 Subscribe for More Information |
|
| May 21, 2013 |
| 16:51 EDT |  | GILD | Gilead's sofosbuvir gets EMA validation, now under assessment
Subscribe for More Information |
|
| May 20, 2013 |
| 07:34 EDT | | GILD | UBS to host a conference
Subscribe for More Information |
|
| May 16, 2013 |
| 11:50 EDT | | GILD | Celgene, Gilead lower after new data published at ASCO
Subscribe for More Information |
|
| May 15, 2013 |
| 18:32 EDT | | GILD | Gilead announces response data from Phase 2 study of Idelalisib
Subscribe for More Information |
|
| May 13, 2013 |
| 09:39 EDT |  | GILD | Active equity option families trading
Active equity option families trading on open according to Track Data: AAPL C TSLA LVS GILD FSLR |
|
|
|
|
|
